Alimera Sciences (ALIM) Release: ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema  
4/24/2012 10:02:44 AM

ATLANTA, April 24, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the Austrian Agency for Health and Food Safety (Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit, AGES) has granted marketing authorization to ILUVIENĀ® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.